• Former President Donald Trump escalates pressure on pharmaceutical giants, singling out Eli Lilly with a 60-day action demand.
  • The move signals renewed federal scrutiny on drug pricing, manufacturing, or compliance amid record industry profits.
  • Analysts watch for potential ripple effects across the sector as political focus intensifies ahead of the election cycle.

Trump Administration Turns Up Heat on Big Pharma

The White House confirmed Thursday that former President Donald Trump took direct action against the pharmaceutical industry, sending letters to CEOs—including a pointed directive to Eli Lilly & Co. demanding "specific actions" within 60 days. While the exact contents of the letters remain undisclosed, sources familiar with the matter suggest the administration is pushing for concessions on drug pricing or domestic manufacturing commitments.

Eli Lilly, the world’s most valuable drugmaker with an $842 billion market cap, finds itself squarely in the crosshairs. The company’s blockbuster diabetes and obesity drugs—Mounjaro and Zepbound—have driven record revenues ($34.1 billion in 2024) while drawing criticism over accessibility. "When you see a 60-day deadline, it’s typically about extracting a public pledge," noted one healthcare policy analyst. "The administration wants visible wins on affordability before November."

A Familiar Playbook with New Stakes

This isn’t Trump’s first clash with pharma. During his presidency, he issued executive orders targeting insulin pricing and floated "most favored nation" rules to tie U.S. drug costs to international benchmarks. But the latest move comes as Lilly and rivals like Novo Nordisk face supply shortages for weight-loss drugs, compounding political tensions. "They’re leveraging the spotlight," said a former FDA official. "With Lilly’s stock up 80% in 12 months, the optics of squeezing them are irresistible."

Investors initially brushed off the news, with Lilly shares dipping less than 1% in afternoon trading. Yet the 60-day clock introduces uncertainty. Past federal pressure campaigns—such as Biden’s threats to revoke patents for high-cost medications—have spurred voluntary price freezes. But without legislative teeth, outcomes often hinge on backroom negotiations. Lilly declined to comment, though insiders hint at ongoing "constructive" talks with regulators.

What Comes Next?

All eyes are on whether Lilly will preemptively announce price caps or expanded patient assistance programs. The company has precedent here: In 2023, it slashed insulin costs by 70% following public outrage. Broader implications loom, too. With the Inflation Reduction Act already empowering Medicare to negotiate drug prices, the industry faces a regulatory pincer movement. "This isn’t just about one company," warned a hedge fund manager with pharma holdings. "It’s a warning shot to the entire sector."